Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

203.80DKK
25 May 2018
Change (% chg)

kr.-5.50 (-2.63%)
Prev Close
kr.209.30
Open
kr.212.00
Day's High
kr.212.00
Day's Low
kr.201.40
Volume
466,097
Avg. Vol
451,305
52-wk High
kr.444.00
52-wk Low
kr.158.55

Chart for

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.64
Market Cap(Mil.): kr.6,571.54
Shares Outstanding(Mil.): 32.25
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): 903.81 29.19 33.30
EPS (TTM): 0.23 -- --
ROI: 0.21 13.53 13.04
ROE: 0.23 15.25 14.90

BRIEF-Bavarian Nordic FY EBIT Rises To DKK 353.2‍​ Million

* FY EBIT DKK 353.2‍​ MILLION VERSUS DKK 33.0 MILLION YEAR AGO

Mar 12 2018

BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer

* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER

Mar 08 2018

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

Mar 06 2018

BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab

* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS

Feb 26 2018

BRIEF-Bavarian Nordic Announces Positive Results Of Pivotal Phase 3 Study Of Imvamune Smallpox Vaccine

* BAVARIAN NORDIC ANNOUNCES POSITIVE RESULTS OF PIVOTAL PHASE 3 STUDY OF IMVAMUNE® SMALLPOX VACCINE

Feb 06 2018

BRIEF-Bavarian Nordic Announces Planned Departure Of CFO Ole Larsen

* BAVARIAN NORDIC ANNOUNCES THE PLANNED DEPARTURE OF CHIEF FINANCIAL OFFICER, OLE LARSEN

Jan 31 2018

BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

Jan 19 2018

Merkel's allies, further defying SPD, seek cuts to tax and asylum seeker benefits

BERLIN Germany's Bavarian conservatives are pressing for corporate tax cuts and cuts to welfare payments for asylum seekers, which could complicate talks with the Social Democrats (SPD) on forming a new government.

Jan 01 2018

Earnings vs. Estimates